| Record Nr. | UNINA9910373905103321 |
|-------------------------|--|
| Titolo | Pathogenicity and Drug Resistance of Human Pathogens : Mechanisms and Novel Approaches / / edited by Saif Hameed, Zeeshan Fatima |
| Pubbl/distr/stampa | Singapore : , : Springer Singapore : , : Imprint : Springer, , 2019 |
| ISBN | 981-329-449-3 |
| Edizione | [1st ed. 2019.] |
| Descrizione fisica | 1 online resource (XXIV, 404 p. 52 illus., 43 illus. in color.) |
| Disciplina | 616.9041 |
| Soggetti | Parasitology Infectious diseases Drug resistance Bioinformatics Virology Infectious Diseases Drug Resistance Resistència als medicaments Patologia Llibres electrònics |
| Lingua di pubblicazione | Inglese |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Nota di contenuto | Module 1_Pathogenicity and Drug resistance in Mycobacterium tuberculosis Module 2_ Candida infections and therapeutic strategies Module 3_Malarial parasite biology Module 4_ Emerging Viral Diseases Module 5_Translational Research in Human Microbes. |
| Sommario/riassunto | The book comprehensively discusses the mechanisms of pathogenesis and drug resistance; current diagnostics landscape of four key human pathogens; bacterial, fungal, protozoans and viral which are the causes of major infectious diseases. It also assesses the emerging technologies for the detection and quantification of these pathogens. Further, it discusses the novel opportunities to fight against these infectious diseases and to identify pertinent drug targets with novel methodologies. It also reviews the current and future insights into the |

1.

control, elimination, and eradication of these infectious diseases. Importantly, the book discusses the epidemiological characteristics and various challenges in combating Ebola and Influenza diseases. Finally, the book highlights the growing role of nanotechnology and bioinformatics resources for combating the infectious diseases. In summary, the book provides the mechanistic insight of the pathogenicity, drug-resistance, therapeutic strategies and identification of the novel drug targets of Mycobacterium tuberculosis, Plasmodium, Candida, Hepatitis C and emerging viral infections.